Reading Time: 2 minutesIntroduction Lymphoma remains one of the most prevalent hematologic malignancies among American males, with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) accounting for over 40,000 new cases annually in this demographic, per Surveillance, Epidemiology, and End Results (SEER) data. Chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) induce profound catabolic states, leading to sarcopenia, fatigue, and protracted recovery periods. Traditional supportive therapies—nutritional supplementation, exercise, and erythropoietin-stimulating agents—often fall short in restoring lean body mass (LBM) and functional status. Serostim, a recombinant human growth hormone (rhGH), has emerged as a promising adjunctive therapy. This … Continue reading →